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Abstract: Optical tweezers are proven indispensable single-cell micro-manipulation and
mechanical phenotyping tools. In this study, we have used optical tweezers for measuring the
viscoelastic properties of human red blood cells (RBCs). Comparison of the viscoelastic features
of the healthy fresh and atorvastatin treated cells revealed that the drug softens the cells. Using
a simple modeling approach, we proposed a molecular model that explains the drug-induced
softening of the RBC membrane. Our results suggest that direct interactions between the drug
and cytoskeletal components underlie the drug-induced softening of the cells.
© 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
OCIS codes: (350.4855) Optical tweezers or optical manipulation; (170.4520) Optical confinement and manipulation;
(000.1430) Biology and medicine; (170.1420) Biology.
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1. Introduction
Blood plays a vital role in maintaining physiological homeostasis in the human body. This
non-newtonian colloidal liquid can transport a large number of species, such as respiratory
gasses, nutrients and drugs, all over the entire body. It is believed that rheological behavior of
this compound fluid is in close relation with its function [1]. For instance, physical deformation
of the Red Blood Cells (RBCs) underlies pathological manifestations of sickle cell anemia and
hypercholesterolemia. Therefore, one can expect a correlation between the physical properties
of RBC and the state of overall health of the cell [2]. In this regards a large scientific effort is
focussed on mechanical properties of RBC [2–4].
Cholesterol content of RBC membrane is a major determinant of RBC mechanics and
is significantly altered in hypercholesterolemia, a disorder that dramatically increases the
risk of developing cardiovascular diseases [5]. Cholesterol plays a crucial role in structural
integrity and functioning of the membrane of the RBCs. An increase or decrease in the level of
membrane cholesterol could alter vital processes such as membrane trafficking, cell signaling
as well as membrane phase behaviour [5]. Statins-family of drugs are commonly prescribed for
hypercholesterolemia patients with both primary and secondary prevention in order to decrease
the level of the blood cholesterol. Statin drugs, thus affect RBC mechanics indirectly through
modulation of cholesterol content of the membrane [6]. It is however unclear whether statin drug
can directly affect RBC mechanics, or more broadly, mechanics of human cells.
In this article, we ask whether statin drugs directly affect mechanical properties of human
RBCs or not. We study Atorvastatin, a commonly prescribed statin drug, and show that it can
affect the mechanical properties of human RBC. We compare the viscoelastic properties of
healthy and Atorvastatin-treated RBC at single-cell level using Optical Tweezers (OT). OT are
commonly used for single-cell mechanical studies due to their better resolution for piconewton
range forces. we propose a mechanism that explains the observed softening. This is achieved
by performing molecular modeling analysis of the interactions between Atorvastatin and RBC
membrane. Our results reveal molecular interactions between drug and cytoskeleton proteins.
We find that Atorvastatin induces protein conformational changes that may lead to a significant
increase in the flexibility of the cell.
2. Material and methods
2.1. Sample preparation
All samples were prepared using sterile normal saline (PSS) containing 9 mg/ml NaCl solution.
Blood samples were first taken from healthy volunteers using sterile finger picks and then diluted
in PSS, after which were incubated with the drug solution for about 10 minutes. In order to
prepare the drug solution, first, a small amount of the drug was dissolved in PSS by sonication at
37◦C for 60 minutes. After flushing the solution through a 0.25µm filter the final concentration
of the drug solution was set to 0.7µg/ml [7].
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2.2. Optical micromanipulation setup
Our OT setup consists of a CW laser source (Nd:YAG, λ=1064nm, Coherent) implemented
in a home-designed inverted microscope. The collimated laser beam is focused using a high
Numerical Aperture (NA) objective lens (UPlanSAPo, 60×, NA=1.20, Water, Olympus). The
sample chamber holder is mounted on a piezo stage (P-753.21C, Physik Instrumente). This allows
for spatial nano-positioning of the trap inside the sample chamber. A Quadrant Photo Diode(QPD)
positioned at the back focal plane of the condenser allows for measuring the displacements of
the trapped bead from the center of the trap with nanometer spatial and megahertz temporal
resolutions. In a typical measurement the RBC of interest was firmly attached to two separate
polystyrene beads from its diagonal sides, as it is schematically shown in the inset of Fig. 1(b). In
the final experimental assay the large bead (∼4µm, Anti-dig polystyrene, Kisker Biotech) was
attached to the glass chamber wall using van der waals interaction, whereas the small bead (∼2µm,
Anti-dig polystyrene, Kisker Biotech) was optically trapped. The attachment of the beads to the
cell’s membrane was done by conjugation of the anti-dig (on the bead’s surface) and the cell’s
surface proteins with carbohydrate residues (including Band-3 protein). It should be mentioned
that before attaching the small bead to the cell the trap was calibrated. In order to do that, first,
the voltages of the QPD were recorded for three seconds at a sampling rate of 22kHz. The trap
stiffness and the voltage-to-position conversion factor were obtained by power spectrum analysis
of the recorded time series. It is worth mentioning that the size of the trapped bead was chosen so
that the cell was not directly exposed to the laser beam, even in the most displaced position.
2.3. Manipulation cycle
The entire measurement was conducted in a cyclic manner, in which the cell is periodically
subjected to an external tensile force followed by a relaxation time. More specifically, the
manipulation cycle consisted of four separate steps as follows: Step 1(stretch): the cell was
stretched with a pre-known strain rate. This was done by translating the sample chamber with a
pre-known velocity for 2µm. Due to its viscoelastic nature, the cell may show a wide range of
stiffnesses for this step depending on the velocity that it is pulled out. Step 2 (relax): The stage
was kept stationary for over 20 seconds. In this step the cell is given a time to relax the exerted
tension and come to a mechanical equilibrium. Step 3: The sample chamber was moved back
by 2µm at the same velocity used in step 1. Step 4: The sample chamber was kept stationary
for over 20 seconds in order to let the RBC relax, again. During the entire process the force
experienced by the trapped bead was monitored at a sampling rate of 5kHz. Typical force-time
and force-displacement graphs for a Healthy-Fresh (HF) and Drug-Treated (DT) RBCs are shown
in Fig. 1(a) and 1(b), respectively.
2.4. Molecular docking
Molecular docking was carried out using Autodock suit version 4.3 [8] and MGL tools version
1.5.6 [9] with standard parameters. The molecular structure of Atorvastatin was created and energy
minimized using PRODRG2 online server [10]. The molecular structure of the spectrin-binding
domain of ankyrin and F-actin were obtained from the protein data bank with PDB codes of
3KBT and 3J8A, respectively. The proteins’ structure were checked for missing atoms and any
possible bad contacts and clashes was fixed using Molprobity online server [11].
3. Results and discussion
In order to compare the viscoelastic properties of HF and DT cells the manipulation cycle was
repeated on the two cell types. In the following, different aspects of the response graphs will be
discussed. The results are based on 26 HF and 17 DT manipulation cycles.
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Fig. 1. The measured force as a function of: (a) time, and (b) elongation in a typical
manipulation cycle. Each step is shown using a separate color code to be distinguishable.
Inset: (a) The relaxation data for the healthy-fresh (red squares) and drug-treated (red circles)
of the main graph are fitted to a power law decay function (equation 1).
3.1. Stress relaxation study
Typical relaxation graphs for the Healthy-Fresh (HF) and Drug-Treated (DT) cells are shown in
the inset of Fig. 1. This relaxation is mainly due to the rearrangement of cytoskeletal network
in response to the external tensile stress [12]. The previous studies have shown that during this
relaxation the holding force can be expressed using a power-law decay function [2]. Therefore,
the recorded relaxation data were fitted to the following function [4]
F(t) = ∆F0 × ( tt0 )
−αf + Fin f (1)
where F(t),∆F0, αf , and Fin f denote the measured force at time t, final force value (corresponding
to the plateau), relaxation time constant, and a constant, respectively. In order to use dimensionless
time, t0 was set to 1s. Note that the value of αf obtained in this step is independent of the strain
rate used in step 1. Fitting the relaxation graphs to equation 1 (Fig. 1(a)-inset) resulted in αf
of 0.25±0.03 and 0.34±0.03, respectively, for the HF and DT cells. It is previously shown that
an ATP dependent internal metabolism could alter the relaxation power, αf [13]. Therefore,
one possible reason for the slight difference in the αf values of the two cell types could be that
the metabolism pathway and re-association of the protein network is being altered by the drug
molecules attached to the cytoskeletal proteins. As it can be seen from molecular docking results
relatively strong binding of Atorvastatin to two important cytoskeletal junctions would be a
possible reason for alteration of cytoskeleton re-association. It is worth mentioning that at the
strain rates used in this research (step 1 of the cycles) though the initial force of the relaxation
graph could be different, however, the resulted values for αf were the same within the error bars.
3.2. Dynamic stiffness study
As mentioned earlier, the cell is pulled out at a constant strain rate in step 1 of the manipulation
cycle. Therefore, the dynamic stiffness of the cell can be obtained from the slope of the force-
elongation graph (black symbols in Fig. 1(b)). In order to determine the dependency of the
dynamic stiffness on the strain rate, the manipulation cycle was repeated at different strain rates,
the results of which are summarized in Fig. 2(a). It is shown that the dynamic stiffness of the cell
should be a power-law function of the strain rate as below [4]
K( Û) = ∆K( Û) + K0 = ∆K0 × ( ÛÛ0 )
−αk + K0 (2)
where k0 and αk , respectively, denote the stiffness at Û=0 s−1, and the power factor. Note that K0
(can be considered as stationary stiffness) should be independent of the strain rate. By fitting the
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dynamic stiffness graphs to Eq. (2) we obtained αk of 0.39±0.04 and 0.54±0.03, respectively, for
the HF and DT cells. Note that the power factor resulted for the HF cell is in good agreement with
the previous reports [14], and that the lower k0 of the DT cells is accompanied by a larger power
factor compared to the HF cells. In other words though the DT cells seem softer at zero strain
rate, however, their stiffness grows faster when the strain rate is increased. But, in all of the strain
rates used in this research the DT cell seemed to be softer than the HF cells. The inset of Fig. 2(a)
shows the histogram of the resulted stiffness at a strain rate of 0.37 s−1. At this strain rate, the
dynamic stiffness for the HF and DT cells, respectively, were 4.5±0.2pN/µm and 3.6±0.3 pN/µm,
which reveals that the DT cells are softer by ∼25%. It should be mentioned that the histogram
graphs were put under student T-test and the graphs are indeed distinguishable.
3.3. Dissipated energy study
The hysteresis-type behavior shown in Fig. 1(b) reveals that there is a dissipated energy in each
cycle. The amount of the dissipated energy in each cycle can be estimated by the area inside
the force-elongation graph (Fig. 1(b)). The larger the area the larger the dissipated energy. Fig
2(b) shows how the dissipated energy depend on the strain rate. It is theoretically shown that the
dissipated energy should be a power-law decay function of the strain rate as below [4]
Edissp = E0 + E( ÛÛ0 )
αE (3)
The solid lines in Fig. 2(b) show fit to Eq. (3) with resulted power factors (αE ) of 0.63±0.02 and
0.7±0.01, respectively, for the HF and DT cells.
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Fig. 2. Comparison of the HF and DT cells: (a) Dynamic stiffness as a function of strain rate.
The solid lines are the fits to the power-law decay function (Eq. (2)). Inset: Histogram of the
resulted stiffnesses for HF and DT cells at strain rate of 0.37 s−1. (b) The dissipated energy
as a function of the strain rate. The solid lines are fits to Eq. (3).
3.4. Molecular modeling
It is known that the total stiffness of the cell is mainly dominated by its spectrin network. Therefore,
it is very likely that the observed softening in the cell occurs due to the interaction between
the Atorvastatin molecule and the spectrin network of the cell. In order to test this hypothesis,
a molecular docking study was carried out. In this study the spectrin-binding domain of the
ankyrin and f-actin proteins were chosen as targets for the Atorvastatin molecule. Fig. 3 shows a
3-D visualization of the drug molecule next to the proteins, in which the spatial fitting of the
molecule in the surface clefts are shown. The molecular docking results showed that Atorvastatin
molecule has a large affinity to attach to either of the proteins due to the nearly perfect molecular
shape-matching. Apart from the spatial geometry, the polarity complementarity may also assist
this fitting. In order to see this more clearly in the figure, the non-polar, positively charged, and
negatively charged residues are shown in white, blue, and red, respectively. Fig. 3 shows that the
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polar tail of the Atorvastatin molecule has a good tendency to approach the positively charged
polar regions in both of the proteins. Furthermore, the aromatic rings of the drug molecule may
also be positioned in the non-polar cleft in both of the proteins. Besides, in both cases some
hydrogen bonds are created between the drug molecule and the proteins. The above mentioned
points further suggest that the drug molecules may be attached to the spectrin network of the
cell, which could explain the observed softening of the cell upon Atorvastatin treatment. It was
reported that proteolytic dissociation of spectrin-ankryne complex or extraction of actin junctions
remarkably reduced stiffness of RBCs [14]. According to our results, in a similar way the drug
binding could loosen the junctional proteins interaction and, therefore, reduce the stiffness of the
RBCs.
Fig. 3.Molecular docking results: Three dimensional surfacemap showing how aAtorvastatin
molecule interacts with f-actin (left), and spectrin-binding-domain of ankryn (right).
4. Conclusion
Statin family of drugs are commonly used for prevention and treatment of several diseases,
including cardiovascular diseases and cancer [15], yet cellular responses to statin drugs have not
been fully investigated. In addition to its lipid lowering effect, several beneficial are observed for
this drug family, including the anti-inflammatory effect [16], reduced isoprenylation of proteins,
and inhibition of GTPases [15]. Moreover, several side effects have been reported for this drug
family, including hepatoxicity [17], rhabdomyolysis, and muscular problems [18]. Here, we
studied the effects of a statin drug on cellular mechanics. More specifically, we studied the effects
of atorvastatin on RBC mechanics. According to our experimental results the atorvastatin treated
human red blood cells are softer than the healthy-fresh red blood cells. Our molecular docking
results show that the atorvastatin molecule has a relatively high affinity to bind to the spectrin
binding domain of ankyrin and F-actin proteins due to the shape and charge complementarity.
Such a binding could alter the proteins conformation as it can change the strength of the native
interactions in the junctions. This could even cause dissociation in some of the junctions in the
cytoskeletal network leading to a total softening of the cell [14]. Further molecular investigation in
this regard, such as all-atom molecular dynamics simulations, could reveal valuable information.
It is known that the drugs designed for a specific treatment may also have some other side-effects.
In some cases the side effect may even be considered as a possibility to use against another related
(or even completely different) disease. This means that this drug may also be used against the
RBC hardening diseases.
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